Insider-Transaktionen

EDGAR

SPYRE THERAPEUTICS, INC.

Von Direktoren, Führungskräften und 10-%-Eignern auf den SEC-Formularen 3, 4 und 5 gemeldete Transaktionen, aus dem XML jeder Einreichung gelesen. Codes und ihr Wortlaut stammen von der SEC.

Das Formular 4 ist innerhalb von zwei Geschäftstagen nach der Transaktion einzureichen; die jüngsten Geschäfte sind daher möglicherweise noch nicht gemeldet.

Zeitfenster: Transaktionen ab dem 16. Nov. 2025.

Käufe am offenen Markt (Code P)
0 Transaktionen, — Aktien
Verkäufe am offenen Markt (Code S)
94 Transaktionen, 5.243.803 Aktien
Summe Aktien × Preis je Aktie: 441.932.902,2

Die Summen addieren die aufgeführten eingereichten Transaktionen; sie zählen das Gemeldete und messen keine Richtung.

1–50 von 143 angezeigt

Insider-Transaktionen, neueste zuerst, wie auf den SEC-Formularen 3, 4 und 5 eingereicht
DatumMeldende PersonCodeErworben oder veräußertAktienPreis je Aktie, wie eingereichtWert (abgeleitet)Aktien danach im BesitzDirekt oder indirektKästchen zu Rule 10b5-1AnmerkungenQuelle
1. Okt. 2026 Eingereicht am 2. Okt. 2026Turtle Cameron Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)60089,14
53.484

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 53484.00.

551.940Direkt (D) Ja
F1, F2, F3
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
  • F2 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the range.
  • F3 Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
Einreichung öffnen 0001636282-26-000118 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Okt. 2026 Eingereicht am 2. Okt. 2026Turtle Cameron Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)2.68390,10
241.738,3

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 241738.30.

549.257Direkt (D) Ja
F1, F4, F3
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
  • F4 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.80 to $90.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • F3 Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
Einreichung öffnen 0001636282-26-000118 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Okt. 2026 Eingereicht am 2. Okt. 2026Turtle Cameron Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)2.63891,49
241.350,62

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 241350.62.

546.619Direkt (D) Ja
F1, F5, F3
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
  • F5 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.85 to $91.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • F3 Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
Einreichung öffnen 0001636282-26-000118 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Okt. 2026 Eingereicht am 2. Okt. 2026Turtle Cameron Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)3.98992,31
368.224,59

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 368224.59.

542.630Direkt (D) Ja
F1, F6, F3
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
  • F6 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.87 to $92.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • F3 Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
Einreichung öffnen 0001636282-26-000118 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Okt. 2026 Eingereicht am 2. Okt. 2026Turtle Cameron Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)4.99093,37
465.916,3

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 465916.30.

537.640Direkt (D) Ja
F1, F7, F3
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
  • F7 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.89 to $93.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • F3 Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
Einreichung öffnen 0001636282-26-000118 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Okt. 2026 Eingereicht am 2. Okt. 2026Turtle Cameron Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)10093,91
9.391

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 9391.00.

537.540Direkt (D) Ja
F1, F3
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
  • F3 Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
Einreichung öffnen 0001636282-26-000118 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Okt. 2026 Eingereicht am 2. Okt. 2026Burrows Scott L Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Erworben (A)7.50014,50
108.750

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 108750.00.

87.262Direkt (D) Ja
F2
  • F2 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
Einreichung öffnen 0001636282-26-000117 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Okt. 2026 Eingereicht am 2. Okt. 2026Burrows Scott L Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)60089,07
53.442

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 53442.00.

86.662Direkt (D) Ja
F2, F3
  • F2 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
  • F3 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the range.
Einreichung öffnen 0001636282-26-000117 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Okt. 2026 Eingereicht am 2. Okt. 2026Burrows Scott L Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)1.50090,27
135.405

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 135405.00.

85.162Direkt (D) Ja
F2, F4
  • F2 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
  • F4 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Einreichung öffnen 0001636282-26-000117 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Okt. 2026 Eingereicht am 2. Okt. 2026Burrows Scott L Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)2.10091,92
193.032

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 193032.00.

83.062Direkt (D) Ja
F2, F5
  • F2 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
  • F5 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.41 to $92.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Einreichung öffnen 0001636282-26-000117 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Okt. 2026 Eingereicht am 2. Okt. 2026Burrows Scott L Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)3.07192,95
285.449,45

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 285449.45.

79.991Direkt (D) Ja
F2, F6
  • F2 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
  • F6 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.54 to $93.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Einreichung öffnen 0001636282-26-000117 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Okt. 2026 Eingereicht am 2. Okt. 2026Burrows Scott L Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)22993,57
21.427,53

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 21427.53.

79.762Direkt (D) Ja
F2, F7, F8
  • F2 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
  • F7 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.54 to $93.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • F8 Includes 33,738 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of the Issuer's common stock. The RSUs vest on September 1, 2027, subject to the Reporting Person's continued employment with the Issuer.
Einreichung öffnen 0001636282-26-000117 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Okt. 2026 Eingereicht am 2. Okt. 2026Burrows Scott L Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (7.500) — Ausübungspreis 14.50
Veräußert (D)7.5000—312.357Direkt (D) Ja
F2, F9
  • F2 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
  • F9 This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Einreichung öffnen 0001636282-26-000117 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Okt. 2026 Eingereicht am 2. Okt. 2026King-Jones Heidy Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Erworben (A)28.93314,50
419.528,5

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 419528.50.

31.778Direkt (D) Ja
F1
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
Einreichung öffnen 0001636282-26-000119 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Okt. 2026 Eingereicht am 2. Okt. 2026King-Jones Heidy Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)40089,24
35.696

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 35696.00.

31.378Direkt (D) Ja
F1, F2
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
  • F2 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the range.
Einreichung öffnen 0001636282-26-000119 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Okt. 2026 Eingereicht am 2. Okt. 2026King-Jones Heidy Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)16.60590,35
1.500.261,75

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 1500261.75.

14.773Direkt (D) Ja
F1, F3
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
  • F3 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Einreichung öffnen 0001636282-26-000119 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Okt. 2026 Eingereicht am 2. Okt. 2026King-Jones Heidy Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)7.22891,35
660.277,8

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 660277.80.

7.545Direkt (D) Ja
F1, F4
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
  • F4 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.10 to $92.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Einreichung öffnen 0001636282-26-000119 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Okt. 2026 Eingereicht am 2. Okt. 2026King-Jones Heidy Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)2.10092,70
194.670

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 194670.00.

5.445Direkt (D) Ja
F1, F5
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
  • F5 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.12 to $93.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Einreichung öffnen 0001636282-26-000119 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Okt. 2026 Eingereicht am 2. Okt. 2026King-Jones Heidy Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)2.60093,46
242.996

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 242996.00.

2.845Direkt (D) Ja
F1, F6
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
  • F6 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.17 to $93.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Einreichung öffnen 0001636282-26-000119 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Okt. 2026 Eingereicht am 2. Okt. 2026King-Jones Heidy Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (28.933) — Ausübungspreis 14.50
Veräußert (D)28.9330—482.478Direkt (D) Ja
F1, F7
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
  • F7 This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Einreichung öffnen 0001636282-26-000119 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
30. Sept. 2026 Eingereicht am 2. Okt. 2026Burrows Scott L Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Erworben (A)17.50014,50
253.750

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 253750.00.

97.262Direkt (D) Ja— Einreichung öffnen 0001636282-26-000117 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
30. Sept. 2026 Eingereicht am 2. Okt. 2026Burrows Scott L Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)17.50089,89
1.573.075

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 1573075.00.

79.762Direkt (D) Ja
F1
  • F1 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.00 to $90.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the range.
Einreichung öffnen 0001636282-26-000117 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
30. Sept. 2026 Eingereicht am 2. Okt. 2026Burrows Scott L Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (17.500) — Ausübungspreis 14.50
Veräußert (D)17.5000—319.857Direkt (D) Ja
F9
  • F9 This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Einreichung öffnen 0001636282-26-000117 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
2. Sept. 2026 Eingereicht am 3. Sept. 2026Burrows Scott L Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)18.23289,35
1.629.029,2

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 1629029.20.

79.762Direkt (D) Ja
F6, F7
  • F6 The transaction reported reflects the sale of shares of the Issuer's common stock in satisfaction of the Reporting Person's tax liability in connection with the settlement of 33,738 restricted stock units (RSUs). This sale was made to satisfy tax withholding obligations through a sell to cover transaction and does not represent a discretionary trade made by the Reporting Person.
  • F7 Includes 33,738 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of the Issuer's common stock. The RSUs vest on September 1, 2027, subject to the Reporting Person's continued employment with the Issuer.
Einreichung öffnen 0001636282-26-000109 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
2. Sept. 2026 Eingereicht am 3. Sept. 2026King-Jones Heidy Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Erworben (A)40014,50
5.800

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 5800.00.

3.245Direkt (D) Ja
F1, F2
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
  • F2 Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan.
Einreichung öffnen 0001636282-26-000111 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
2. Sept. 2026 Eingereicht am 3. Sept. 2026King-Jones Heidy Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)40090
36.000

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 36000.

2.845Direkt (D) Ja
F1, F2
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
  • F2 Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan.
Einreichung öffnen 0001636282-26-000111 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
2. Sept. 2026 Eingereicht am 3. Sept. 2026King-Jones Heidy Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (400) — Ausübungspreis 14.50
Veräußert (D)4000—511.411Direkt (D) Ja
F1, F6
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
  • F6 This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Einreichung öffnen 0001636282-26-000111 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Sept. 2026 Eingereicht am 3. Sept. 2026Burrows Scott L Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Erworben (A)7.50014,50
108.750

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 108750.00.

105.494Direkt (D) Ja
F1
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
Einreichung öffnen 0001636282-26-000109 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Sept. 2026 Eingereicht am 3. Sept. 2026Burrows Scott L Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)90086,25
77.625

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 77625.00.

104.594Direkt (D) Ja
F1, F2
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
  • F2 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.60 to $86.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the range.
Einreichung öffnen 0001636282-26-000109 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Sept. 2026 Eingereicht am 3. Sept. 2026Burrows Scott L Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)4.38487,11
381.890,24

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 381890.24.

100.210Direkt (D) Ja
F1, F3
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
  • F3 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.60 to $87.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Einreichung öffnen 0001636282-26-000109 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Sept. 2026 Eingereicht am 3. Sept. 2026Burrows Scott L Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)2.01688,03
177.468,48

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 177468.48.

98.194Direkt (D) Ja
F1, F4
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
  • F4 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.64 to $88.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Einreichung öffnen 0001636282-26-000109 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Sept. 2026 Eingereicht am 3. Sept. 2026Burrows Scott L Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)20089,04
17.808

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 17808.00.

97.994Direkt (D) Ja
F1, F5
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
  • F5 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.69 to $89.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Einreichung öffnen 0001636282-26-000109 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Sept. 2026 Eingereicht am 3. Sept. 2026Burrows Scott L Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (7.500) — Ausübungspreis 14.50
Veräußert (D)7.5000—337.357Direkt (D) Ja
F1, F8
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
  • F8 This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Einreichung öffnen 0001636282-26-000109 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Sept. 2026 Eingereicht am 3. Sept. 2026King-Jones Heidy Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Erworben (A)27.99914,50
405.985,5

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 405985.50.

30.844Direkt (D) Ja
F1, F2
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
  • F2 Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan.
Einreichung öffnen 0001636282-26-000111 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Sept. 2026 Eingereicht am 3. Sept. 2026King-Jones Heidy Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)4.84586,40
418.608

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 418608.00.

25.999Direkt (D) Ja
F1, F3, F2
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
  • F3 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.71 to $86.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the range.
  • F2 Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan.
Einreichung öffnen 0001636282-26-000111 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Sept. 2026 Eingereicht am 3. Sept. 2026King-Jones Heidy Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)16.54887,20
1.442.985,6

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 1442985.60.

9.451Direkt (D) Ja
F1, F4, F2
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
  • F4 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.71 to $87.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • F2 Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan.
Einreichung öffnen 0001636282-26-000111 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Sept. 2026 Eingereicht am 3. Sept. 2026King-Jones Heidy Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)6.20688,17
547.183,02

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 547183.02.

3.245Direkt (D) Ja
F1, F5, F2
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
  • F5 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.73 to $88.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • F2 Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan.
Einreichung öffnen 0001636282-26-000111 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Sept. 2026 Eingereicht am 3. Sept. 2026King-Jones Heidy Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)40089,38
35.752

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 35752.00.

2.845Direkt (D) Ja
F1, F2
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
  • F2 Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan.
Einreichung öffnen 0001636282-26-000111 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Sept. 2026 Eingereicht am 3. Sept. 2026King-Jones Heidy Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (27.999) — Ausübungspreis 14.50
Veräußert (D)27.9990—511.811Direkt (D) Ja
F1, F6
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
  • F6 This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Einreichung öffnen 0001636282-26-000111 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Sept. 2026 Eingereicht am 3. Sept. 2026Turtle Cameron Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)2.50086,36
215.900

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 215900.00.

565.040Direkt (D) Ja
F1, F2, F3
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
  • F2 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.67 to $86.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the range.
  • F3 Includes 43,593 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
Einreichung öffnen 0001636282-26-000107 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Sept. 2026 Eingereicht am 3. Sept. 2026Turtle Cameron Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)8.40087,15
732.060

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 732060.00.

556.640Direkt (D) Ja
F1, F4, F3
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
  • F4 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.67 to $87.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • F3 Includes 43,593 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
Einreichung öffnen 0001636282-26-000107 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Sept. 2026 Eingereicht am 3. Sept. 2026Turtle Cameron Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)3.70088,06
325.822

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 325822.00.

552.940Direkt (D) Ja
F1, F5, F3
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
  • F5 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.68 to $88.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • F3 Includes 43,593 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
Einreichung öffnen 0001636282-26-000107 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Sept. 2026 Eingereicht am 3. Sept. 2026Turtle Cameron Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)40089,07
35.628

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 35628.00.

552.540Direkt (D) Ja
F1, F6, F3
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
  • F6 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.69 to $89.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • F3 Includes 43,593 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
Einreichung öffnen 0001636282-26-000107 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
7. Aug. 2026 Eingereicht am 10. Aug. 2026Albers Jeffrey W. Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Erworben (A)5.00010,39
51.950

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 51950.00.

5.000Direkt (D) Ja
F1
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
Einreichung öffnen 0001636282-26-000102 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
7. Aug. 2026 Eingereicht am 10. Aug. 2026Albers Jeffrey W. Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)5.000104,47
522.350

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 522350.00.

0Direkt (D) Ja
F1, F2
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
  • F2 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.59 to $105.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the range.
Einreichung öffnen 0001636282-26-000102 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
7. Aug. 2026 Eingereicht am 10. Aug. 2026Albers Jeffrey W. Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)8.000104,38
835.040

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 835040.00.

19.360Indirekt (I) By Sessions LLCJa
F1, F3
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
  • F3 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.52 to $105.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Einreichung öffnen 0001636282-26-000102 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
7. Aug. 2026 Eingereicht am 10. Aug. 2026Albers Jeffrey W. Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)10.000104,68
1.046.800

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 1046800.00.

9.360Indirekt (I) By Sessions LLCJa
F1, F4
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
  • F4 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.60 to $106.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Einreichung öffnen 0001636282-26-000102 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
7. Aug. 2026 Eingereicht am 10. Aug. 2026Albers Jeffrey W. Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (5.000) — Ausübungspreis 10.39
Veräußert (D)5.0000—45.000Direkt (D) Ja
F1, F5
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
  • F5 This option represents a right to purchase 50,000 shares of the Issuer's common stock, which vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.
Einreichung öffnen 0001636282-26-000102 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
3. Aug. 2026 Eingereicht am 5. Aug. 2026Turtle Cameron Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)80093,97
75.176

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 75176.00.

581.740Direkt (D) Ja
F1, F2, F3
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
  • F2 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.42 to $94.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the range.
  • F3 Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
Einreichung öffnen 0001636282-26-000099 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
3. Aug. 2026 Eingereicht am 5. Aug. 2026Turtle Cameron Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)7.15795,10
680.630,7

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 680630.70.

574.583Direkt (D) Ja
F1, F4, F3
  • F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
  • F4 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.44 to $95.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • F3 Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
Einreichung öffnen 0001636282-26-000099 Aus dem XML der Einreichung gelesen Diese Zeile anfechten

Institutionelle Halter (Formular 13F)

Quartal zum 2026-09-30: 7.211 Einreichungen gelesen, die jüngste vom 13. Nov. 2026. Vorquartal zum 2026-06-30: 9.150 Einreichungen gelesen.

1–50 von 197 angezeigt

Institutionelle Halter, größte Position zuerst, wie eingereicht
ManagerAktien oder NennbetragWert wie eingereichtDifferenz zum VorquartalQuelle
FMR LLC Teilweise unter einem anderen Manager gemeldet13.496.596 SH1.201.601.942 DollarHöher um 470.409 Vorquartal: 13.026.187Einreichung öffnen 0000315066-26-002964 Eingereicht am 10. Nov. 2026 Diese Zeile anfechten
BlackRock, Inc. Teilweise unter einem anderen Manager gemeldet6.779.486 SH603.577.615 DollarHöher um 272.881 Vorquartal: 6.506.605Einreichung öffnen 0002012383-26-003985 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
VANGUARD PORTFOLIO MANAGEMENT LLC 4.063.789 SH361.799.135 DollarHöher um 1.733.691 Vorquartal: 2.330.098Einreichung öffnen 0002100121-26-001150 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
VANGUARD CAPITAL MANAGEMENT LLC 3.750.793 SH333.933.101 DollarHöher um 302.112 Vorquartal: 3.448.681Einreichung öffnen 0002100119-26-001711 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
STATE STREET CORP Teilweise unter einem anderen Manager gemeldet3.533.862 SH314.608.605 DollarHöher um 476.446 Vorquartal: 3.057.416Einreichung öffnen 0000093751-26-000747 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
GEODE CAPITAL MANAGEMENT, LLC Teilweise unter einem anderen Manager gemeldet2.552.798 SH236.412.673 DollarNiedriger um 9.467 Vorquartal: 2.562.265Einreichung öffnen 0001214717-26-000012 Eingereicht am 6. Nov. 2026 Diese Zeile anfechten
Capital World Investors Teilweise unter einem anderen Manager gemeldet2.364.029 SH210.469.502 DollarHöher um 48.476 Vorquartal: 2.315.553Einreichung öffnen 0001422849-26-000169 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
JPMORGAN CHASE CO Teilweise unter einem anderen Manager gemeldet1.728.140 SH146.774.789 DollarHöher um 635.114 Vorquartal: 1.093.026Einreichung öffnen 0000019617-26-000404 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
FRANKLIN TEMPLETON INC Teilweise unter einem anderen Manager gemeldet1.435.788 SH142.200.443 DollarNiedriger um 37.155 Vorquartal: 1.472.943Einreichung öffnen 0000038777-26-000291 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
Affinity Asset Advisors, LLC 1.279.134 SH113.881.300 DollarUnverändert Vorquartal: 1.279.134Einreichung öffnen 0001011438-26-000687 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
Remedium Capital Partners, LLC Teilweise unter einem anderen Manager gemeldet1.160.620 SH103.329.999 DollarNiedriger um 303.549 Vorquartal: 1.464.169Einreichung öffnen 0002104501-26-000021 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
WESTFIELD CAPITAL MANAGEMENT CO LP 883.904 SH78.693.973 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001177719-26-000022 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
Siren, L.L.C. Teilweise unter einem anderen Manager gemeldet868.598 SH77.331.280 DollarNiedriger um 100.000 Vorquartal: 968.598Einreichung öffnen 0002005245-26-000013 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
UBS Group AG Teilweise unter einem anderen Manager gemeldet839.946 SH74.780.393 DollarNiedriger um 3.125 Vorquartal: 843.071Einreichung öffnen 0001610520-26-000121 Eingereicht am 10. Nov. 2026 Diese Zeile anfechten
Capital International Investors Teilweise unter einem anderen Manager gemeldet630.409 SH56.125.313 DollarNiedriger um 324.787 Vorquartal: 955.196Einreichung öffnen 0001562230-26-000136 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
Clearbridge Investments, LLC 602.519 SH53.642.267 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001348883-26-000026 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
Assenagon Asset Management S.A. 599.224 SH53.348.913 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001546007-26-000008 Eingereicht am 15. Okt. 2026 Diese Zeile anfechten
VANGUARD FIDUCIARY TRUST CO 587.439 SH52.299.694 DollarHöher um 36.050 Vorquartal: 551.389Einreichung öffnen 0000933478-26-000017 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
EMERALD ADVISERS, LLC 571.047 SH50.840.314 DollarHöher um 3.617 Vorquartal: 567.430Einreichung öffnen 0001104659-26-124249 Eingereicht am 9. Nov. 2026 Diese Zeile anfechten
VICTORY CAPITAL MANAGEMENT INC 548.670 SH48.848.090 DollarNiedriger um 5.310 Vorquartal: 553.980Einreichung öffnen 0001040188-26-000051 Eingereicht am 10. Nov. 2026 Diese Zeile anfechten
MARSHALL WACE, LLP Teilweise unter einem anderen Manager gemeldet544.129 SH48.443.805 DollarNiedriger um 447.564 Vorquartal: 991.693Einreichung öffnen 0001318757-26-000012 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
AMERICAN CENTURY COMPANIES INC Teilweise unter einem anderen Manager gemeldet514.892 SH45.841.020 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0000748054-26-000008 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
Pictet Asset Management Holding SA 479.135 SH42.657.389 DollarNiedriger um 149.003 Vorquartal: 628.138Einreichung öffnen 0001993888-26-000007 Eingereicht am 3. Nov. 2026 Diese Zeile anfechten
Candriam S.C.A. 448.570 SH40.082.100 DollarNiedriger um 97.742 Vorquartal: 546.312Einreichung öffnen 0001537014-26-000009 Eingereicht am 3. Nov. 2026 Diese Zeile anfechten
EMERALD MUTUAL FUND ADVISERS TRUST 366.129 SH32.596.465 DollarNiedriger um 35.142 Vorquartal: 401.271Einreichung öffnen 0001104659-26-124247 Eingereicht am 9. Nov. 2026 Diese Zeile anfechten
VOYA INVESTMENT MANAGEMENT LLC Teilweise unter einem anderen Manager gemeldet348.161 SH30.996.774 DollarNiedriger um 83.533 Vorquartal: 431.694Einreichung öffnen 0001068837-26-000006 Eingereicht am 10. Nov. 2026 Diese Zeile anfechten
Nuveen, LLC Teilweise unter einem anderen Manager gemeldet321.427 SH28.616.646 DollarHöher um 140.322 Vorquartal: 181.105Einreichung öffnen 0000930413-26-003284 Eingereicht am 10. Nov. 2026 Diese Zeile anfechten
BNP PARIBAS FINANCIAL MARKETS Teilweise unter einem anderen Manager gemeldet268.217 SH23.879.360 DollarHöher um 8.294 Vorquartal: 259.923Einreichung öffnen 0001166588-26-000012 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
Bank of New York Mellon Corp Teilweise unter einem anderen Manager gemeldet261.592 SH23.289.535 DollarHöher um 16.399 Vorquartal: 245.193Einreichung öffnen 0001390777-26-000121 Eingereicht am 5. Nov. 2026 Diese Zeile anfechten
Fiera Capital Corp Teilweise unter einem anderen Manager gemeldet255.104 SH22.711.909 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001505817-26-000019 Eingereicht am 6. Nov. 2026 Diese Zeile anfechten
EVENTIDE ASSET MANAGEMENT, LLC 252.075 SH22.433.294 DollarHöher um 50.459 Vorquartal: 201.616Einreichung öffnen 0001580642-26-007711 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
Universal- Beteiligungs- und Servicegesellschaft mbH Teilweise unter einem anderen Manager gemeldet175.769 SH15.648.714 DollarHöher um 2.846 Vorquartal: 172.923Einreichung öffnen 0002057170-26-000022 Eingereicht am 10. Nov. 2026 Diese Zeile anfechten
DEUTSCHE BANK AG\ Teilweise unter einem anderen Manager gemeldet171.199 SH15.241.847 DollarNiedriger um 3.260 Vorquartal: 174.459Einreichung öffnen 0000948046-26-000083 Eingereicht am 6. Nov. 2026 Diese Zeile anfechten
BARCLAYS PLC Teilweise unter einem anderen Manager gemeldet155.490 SH13.843.274 DollarHöher um 61.421 Vorquartal: 94.069Einreichung öffnen 0000312069-26-000241 Eingereicht am 6. Nov. 2026 Diese Zeile anfechten
SILVERARC CAPITAL MANAGEMENT, LLC 151.151 SH13.456.974 DollarHöher um 91.192 Vorquartal: 59.959Einreichung öffnen 0001420506-26-002577 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
Russell Investments Group, Ltd. Teilweise unter einem anderen Manager gemeldet145.731 SH12.974.557 DollarHöher um 10.974 Vorquartal: 134.757Einreichung öffnen 0001193125-26-451241 Eingereicht am 6. Nov. 2026 Diese Zeile anfechten
NEUBERGER BERMAN GROUP LLC 126.496 SH11.261.939 DollarNiedriger um 54.388 Vorquartal: 180.884Einreichung öffnen 0001465109-26-000128 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
MORGAN STANLEY Teilweise unter einem anderen Manager gemeldet124.938 SH11.123.371 DollarNiedriger um 375.025 Vorquartal: 499.963Einreichung öffnen 0000895421-26-000309 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
Swiss National Bank 123.900 SH11.030.817 DollarHöher um 11.400 Vorquartal: 112.500Einreichung öffnen 0001582202-26-000008 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
TD ASSET MANAGEMENT INC 118.654 SH10.052.367 DollarHöher um 2.664 Vorquartal: 115.990Einreichung öffnen 0001193125-26-460060 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
Ensign Peak Advisors, Inc 109.380 SH9.738.101 DollarNiedriger um 17.240 Vorquartal: 126.620Einreichung öffnen 0001454984-26-000011 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
WCM INVESTMENT MANAGEMENT, LLC 106.492 SH9.022.002 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001062993-26-005874 Eingereicht am 10. Nov. 2026 Diese Zeile anfechten
MANUFACTURERS LIFE INSURANCE COMPANY, THE Teilweise unter einem anderen Manager gemeldet101.771 SH9.060.672 DollarNiedriger um 2.745 Vorquartal: 104.516Einreichung öffnen 0001145443-26-000111 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
Empowered Funds, LLC Teilweise unter einem anderen Manager gemeldet99.816 SH8.886.618 DollarHöher um 97.085 Vorquartal: 2.731Einreichung öffnen 0001592828-26-000008 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
RHUMBLINE ADVISERS 96.966 SH8.632.867 DollarHöher um 2.203 Vorquartal: 94.763Einreichung öffnen 0001115418-26-000015 Eingereicht am 10. Nov. 2026 Diese Zeile anfechten
F/m Investments LLC 95.800 SH8.529.074 DollarHöher um 3.182 Vorquartal: 92.618Einreichung öffnen 0001834499-26-000012 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
Invesco Ltd. Teilweise unter einem anderen Manager gemeldet95.388 SH8.492.394 DollarNiedriger um 25.153 Vorquartal: 120.541Einreichung öffnen 0000914208-26-000462 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
SEB Asset Management AB 89.950 SH8.008.236 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0002127509-26-000006 Eingereicht am 4. Nov. 2026 Diese Zeile anfechten
FEDERATED HERMES, INC. Teilweise unter einem anderen Manager gemeldet88.817 SH7.907.378 DollarHöher um 2.867 Vorquartal: 85.950Einreichung öffnen 0001623632-26-001675 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
Rhenman Partners Asset Management AB 78.600 SH6.997.758 DollarNiedriger um 40.700 Vorquartal: 119.300Einreichung öffnen 0001213900-26-118330 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
Manager des Vorquartals ohne gelesene Einreichung für das neueste

Sie haben möglicherweise nur noch nicht eingereicht: Das Fehlen in den gelesenen Einreichungen des neuesten Quartals bedeutet nicht, dass die Position verkauft wurde.

  • PERCEPTIVE ADVISORS LLC 4.319.496 SH
  • RTW INVESTMENTS, LP 4.251.996 SH
  • Paradigm Biocapital Advisors LP 3.840.778 SH
  • Venrock Adviser, LLC 2.985.448 SH
  • PRICE T ROWE ASSOCIATES INC /MD/ 2.960.855 SH
  • Driehaus Capital Management LLC 2.799.166 SH
  • Jupiter Topco LLC 2.206.936 SH
  • TCG Crossover Management, LLC 1.900.582 SH
  • TANG CAPITAL MANAGEMENT LLC 1.892.200 SH
  • BANK OF AMERICA CORP /DE/ 1.777.854 SH
  • ADAGE CAPITAL PARTNERS GP, L.L.C. 1.722.300 SH
  • WELLINGTON MANAGEMENT GROUP LLP 1.581.505 SH
  • GOLDMAN SACHS GROUP INC 1.478.059 SH
  • Holocene Advisors, LP 1.015.170 SH
  • Polar Capital Holdings Plc 988.009 SH
  • BRAIDWELL LP 879.467 SH
  • Commodore Capital LP 846.786 SH
  • NORTHERN TRUST CORP 674.529 SH
  • Sixth Street Partners Management Company, L.P. 652.958 SH
  • CHARLES SCHWAB INVESTMENT MANAGEMENT INC 652.958 SH
  • UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 522.071 SH
  • SAMLYN CAPITAL, LLC 400.075 SH
  • AMERIPRISE FINANCIAL INC 356.082 SH
  • Integral Health Asset Management, LLC 325.000 SH
  • Woodline Partners LP 306.049 SH
  • JENNISON ASSOCIATES LLC 303.180 SH
  • ADAR1 Capital Management, LLC 283.982 SH
  • Bellevue Group AG 229.931 SH
  • Cormorant Asset Management, LP 225.000 SH
  • SEVEN GRAND MANAGERS, LLC 225.000 SH
  • MILLENNIUM MANAGEMENT LLC 196.712 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 190.400 SH
  • ORBIMED ADVISORS LLC 186.145 SH
  • FRONTIER CAPITAL MANAGEMENT CO LLC 182.931 SH
  • Caption Management, LLC 173.700 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 155.200 SH
  • Balyasny Asset Management L.P. 147.042 SH
  • Soleus Capital Management, L.P. 147.000 SH
  • ARMISTICE CAPITAL, LLC 137.588 SH
  • Blackstone Inc. 120.177 SH
  • STEMPOINT CAPITAL LP 106.926 SH
  • CITADEL ADVISORS LLC 103.100 SH
  • Boxer Capital Management, LLC 100.000 SH
  • ALLIANCEBERNSTEIN L.P. 92.540 SH
  • PRUDENTIAL FINANCIAL INC 87.370 SH
  • Granahan Investment Management, LLC 82.991 SH
  • WELLS FARGO COMPANY/MN 82.506 SH
  • MERCER GLOBAL ADVISORS INC /ADV 71.145 SH
  • B Group, Inc. 70.000 SH
  • Trexquant Investment LP 67.007 SH
  • Das Formular 13F umfasst nur Long-Positionen in Wertpapieren nach Section 13(f): keine Short-Positionen und keine Wertpapiere außerhalb dieser Liste.
  • Ein Manager, der für das neueste Quartal noch nicht eingereicht hat, fehlt und steht nicht bei null; die Frist beträgt bis zu 45 Tage nach Quartalsende.
  • Eine Differenz ist der Unterschied zwischen zwei Quartalsstichtagen, keine Transaktion.
  • Eine unter einem anderen Manager gemeldete Position kann auch in dessen Einreichung erscheinen; die Zeilen werden nicht addiert.
  • Positionen, die die Wertpapierliste diesem Unternehmen nicht oder nur mehrdeutig zuordnen kann, werden nicht angezeigt.

5-%-Halter (Schedule 13D und 13G)

Hier werden im strukturierten SEC-Format (ab Ende 2024) eingereichte Schedules gelesen. Frühere sind Freitext und werden nicht gelesen.

5-%-Halter, jüngstes Ereignis zuerst, wie eingereicht
HalterProzent der GattungGehaltene AktienEreignisdatumFormularQuelle
Fairmount Funds Management LLC Common Stock, $0.0001 par value9.199.354.200,0010/07/2026 Eingereicht am 9. Okt. 2026SCHEDULE 13D/AÄnderung 8Einreichung öffnen 0001104659-26-115087 Diese Zeile anfechten
Fairmount Healthcare Fund II L.P. Common Stock, $0.0001 par value9.199.354.200,0010/07/2026 Eingereicht am 9. Okt. 2026SCHEDULE 13D/AÄnderung 8Einreichung öffnen 0001104659-26-115087 Diese Zeile anfechten
Harwin Peter Evan Common Stock, $0.0001 par value9.9910.185.961,0010/07/2026 Eingereicht am 9. Okt. 2026SCHEDULE 13D/AÄnderung 8Einreichung öffnen 0001104659-26-115087 Diese Zeile anfechten
Kiselak Tomas Common Stock, $0.0001 par value9.9910.185.961,0010/07/2026 Eingereicht am 9. Okt. 2026SCHEDULE 13D/AÄnderung 8Einreichung öffnen 0001104659-26-115087 Diese Zeile anfechten
Paradigm BioCapital Advisors LP Common Stock, $0.0001 par value per share5.14.457.450,0009/24/2026 Eingereicht am 1. Okt. 2026SCHEDULE 13GEinreichung öffnen 0001104659-26-112828 Diese Zeile anfechten
Paradigm BioCapital Advisors GP LLC Common Stock, $0.0001 par value per share5.14.457.450,0009/24/2026 Eingereicht am 1. Okt. 2026SCHEDULE 13GEinreichung öffnen 0001104659-26-112828 Diese Zeile anfechten
Senai Asefaw, M.D. Common Stock, $0.0001 par value per share5.14.457.450,0009/24/2026 Eingereicht am 1. Okt. 2026SCHEDULE 13GEinreichung öffnen 0001104659-26-112828 Diese Zeile anfechten
Paradigm BioCapital International Fund Ltd. Common Stock, $0.0001 par value per share4.53.928.646,0009/24/2026 Eingereicht am 1. Okt. 2026SCHEDULE 13GEinreichung öffnen 0001104659-26-112828 Diese Zeile anfechten
RTW Investments, LP Common Stock, $0.0001 par value4.84.251.996,0006/30/2026 Eingereicht am 14. Aug. 2026SCHEDULE 13G/AÄnderung 2Einreichung öffnen 0001493215-26-000157 Diese Zeile anfechten
Roderick Wong Common Stock, $0.0001 par value4.84.251.996,0006/30/2026 Eingereicht am 14. Aug. 2026SCHEDULE 13G/AÄnderung 2Einreichung öffnen 0001493215-26-000157 Diese Zeile anfechten
Perceptive Advisors LLC Common Stock, $0.0001 Par Value Per Share4.94.319.49606/30/2026 Eingereicht am 14. Aug. 2026SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001193125-26-352655 Diese Zeile anfechten
Joseph Edelman Common Stock, $0.0001 Par Value Per Share4.94.319.49606/30/2026 Eingereicht am 14. Aug. 2026SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001193125-26-352655 Diese Zeile anfechten
Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.0001 Par Value Per Share4.94.319.49606/30/2026 Eingereicht am 14. Aug. 2026SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001193125-26-352655 Diese Zeile anfechten
Fairmount Funds Management LLC Common Stock, $0.0001 par value9.158.835.440,0006/23/2026 Eingereicht am 23. Juni 2026SCHEDULE 13D/AÄnderung 7Einreichung öffnen 0001104659-26-076961 Diese Zeile anfechten
Fairmount Healthcare Fund II L.P. Common Stock, $0.0001 par value9.158.835.440,0006/23/2026 Eingereicht am 23. Juni 2026SCHEDULE 13D/AÄnderung 7Einreichung öffnen 0001104659-26-076961 Diese Zeile anfechten
Peter Evan Harwin Common Stock, $0.0001 par value9.999.667.201,0006/23/2026 Eingereicht am 23. Juni 2026SCHEDULE 13D/AÄnderung 7Einreichung öffnen 0001104659-26-076961 Diese Zeile anfechten
Tomas Kiselak Common Stock, $0.0001 par value9.999.667.201,0006/23/2026 Eingereicht am 23. Juni 2026SCHEDULE 13D/AÄnderung 7Einreichung öffnen 0001104659-26-076961 Diese Zeile anfechten
Fairmount Funds Management LLC Common Stock, $0.0001 par value9.098.184.941,0004/16/2026 Eingereicht am 20. Apr. 2026SCHEDULE 13D/AÄnderung 6Einreichung öffnen 0001104659-26-045578 Diese Zeile anfechten
Fairmount Healthcare Fund II L.P. Common Stock, $0.0001 par value9.098.184.941,0004/16/2026 Eingereicht am 20. Apr. 2026SCHEDULE 13D/AÄnderung 6Einreichung öffnen 0001104659-26-045578 Diese Zeile anfechten
Peter Harwin Common Stock, $0.0001 par value9.999.016.702,0004/16/2026 Eingereicht am 20. Apr. 2026SCHEDULE 13D/AÄnderung 6Einreichung öffnen 0001104659-26-045578 Diese Zeile anfechten
Tomas Kiselak Common Stock, $0.0001 par value9.999.016.702,0004/16/2026 Eingereicht am 20. Apr. 2026SCHEDULE 13D/AÄnderung 6Einreichung öffnen 0001104659-26-045578 Diese Zeile anfechten
Perceptive Advisors LLC Common Stock, $0.0001 Par Value Per Share5.04.319.49604/15/2026 Eingereicht am 22. Apr. 2026SCHEDULE 13GEinreichung öffnen 0001193125-26-170304 Diese Zeile anfechten
Joseph Edelman Common Stock, $0.0001 Par Value Per Share5.04.319.49604/15/2026 Eingereicht am 22. Apr. 2026SCHEDULE 13GEinreichung öffnen 0001193125-26-170304 Diese Zeile anfechten
Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.0001 Par Value Per Share5.04.319.49604/15/2026 Eingereicht am 22. Apr. 2026SCHEDULE 13GEinreichung öffnen 0001193125-26-170304 Diese Zeile anfechten
The Vanguard Group Common Stock0003/13/2026 Eingereicht am 27. März 2026SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0000102909-26-002337 Diese Zeile anfechten
TANG CAPITAL MANAGEMENT, LLC Common Stock, par value $0.0001 per share2.41.892.200,0012/31/2025 Eingereicht am 17. Feb. 2026SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001214659-26-002024 Diese Zeile anfechten
KEVIN TANG Common Stock, par value $0.0001 per share2.41.892.200,0012/31/2025 Eingereicht am 17. Feb. 2026SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001214659-26-002024 Diese Zeile anfechten
TANG CAPITAL PARTNERS, LP Common Stock, par value $0.0001 per share1.31.012.338,0012/31/2025 Eingereicht am 17. Feb. 2026SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001214659-26-002024 Diese Zeile anfechten
TANG CAPITAL PARTNERS INTERNATIONAL, LP Common Stock, par value $0.0001 per share1.1879.862,0012/31/2025 Eingereicht am 17. Feb. 2026SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001214659-26-002024 Diese Zeile anfechten
TANG CAPITAL PARTNERS III, INC Common Stock, par value $0.0001 per share0.00,0012/31/2025 Eingereicht am 17. Feb. 2026SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001214659-26-002024 Diese Zeile anfechten
TANG CAPITAL PARTNERS IV, INC Common Stock, par value $0.0001 per share0.00,0012/31/2025 Eingereicht am 17. Feb. 2026SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001214659-26-002024 Diese Zeile anfechten
Fairmount Funds Management LLC Common Stock, $0.0001 par value8.997.272.341,0010/15/2025 Eingereicht am 17. Okt. 2025SCHEDULE 13D/AÄnderung 5Einreichung öffnen 0001104659-25-100449 Diese Zeile anfechten
Fairmount Healthcare Fund II L.P. Common Stock, $0.0001 par value8.997.272.341,0010/15/2025 Eingereicht am 17. Okt. 2025SCHEDULE 13D/AÄnderung 5Einreichung öffnen 0001104659-25-100449 Diese Zeile anfechten
Peter Evan Harwin Common Stock, $0.0001 par value9.998.106.882,0010/15/2025 Eingereicht am 17. Okt. 2025SCHEDULE 13D/AÄnderung 5Einreichung öffnen 0001104659-25-100449 Diese Zeile anfechten
Tomas Kiselak Common Stock, $0.0001 par value9.998.106.882,0010/15/2025 Eingereicht am 17. Okt. 2025SCHEDULE 13D/AÄnderung 5Einreichung öffnen 0001104659-25-100449 Diese Zeile anfechten
The Vanguard Group Common Stock5.083.066.58606/30/2025 Eingereicht am 29. Juli 2025SCHEDULE 13GEinreichung öffnen 0000932471-25-001050 Diese Zeile anfechten
BlackRock, Inc. Common Stock6.63.962.63506/30/2025 Eingereicht am 16. Juli 2025SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0002052113-25-002469 Diese Zeile anfechten

Der Prozentsatz bezieht sich auf die in der Einreichung genannte Gattung, wie vom Halter angegeben. Gruppenmitglieder melden jeweils die Aktien der Gruppe; die Zeilen werden daher nicht addiert.

Was gelesen wurde

2.092.408 Einreichungen gelesen, vom 14. Juni 2004 bis 13. Nov. 2026: Formulare 3, 3/A, 4, 4/A, 5, 5/A.

Jahre können unvollständig sein, solange das Archiv noch gelesen wird. Ein Jahr mit wenigen Einreichungen hier besagt nicht, dass wenige gemacht wurden.

Gelesene Einreichungen nach Einreichungsjahr
EinreichungsjahrGelesene Einreichungen
20151
2016204.322
2017202.494
2018202.048
2019193.638
2020144.184
2021224.474
202240.015
2023199.811
2024185.386
2025235.520
2026254.737

Einreichungen aus der Zeit vor der XML-Pflicht der SEC sind aufgeführt, aber nicht ausgelesen.

Zurück zu SPYRE THERAPEUTICS, INC.